Log in

CareDx Stock Price, News & Analysis (NASDAQ:CDNA)

-2.37 (-8.34 %)
(As of 10/17/2019 06:59 AM ET)
Today's Range
Now: $26.04
50-Day Range
MA: $23.73
52-Week Range
Now: $26.04
Volume740,346 shs
Average Volume834,945 shs
Market Capitalization$1.10 billion
P/E RatioN/A
Dividend YieldN/A
CareDx, Inc operates as a transplant diagnostics company,which discovers, develops, and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure, and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Industry, Sector and Symbol

Industry Medical laboratories
Current SymbolNASDAQ:CDNA



Sales & Book Value

Annual Sales$76.57 million
Book Value$2.47 per share


Net Income$-46,760,000.00


Market Cap$1.10 billion
Next Earnings Date11/14/2019 (Estimated)

Receive CDNA News and Ratings via Email

Sign-up to receive the latest news and ratings for CDNA and its competitors with MarketBeat's FREE daily newsletter.

CareDx (NASDAQ:CDNA) Frequently Asked Questions

What is CareDx's stock symbol?

CareDx trades on the NASDAQ under the ticker symbol "CDNA."

How were CareDx's earnings last quarter?

CareDx Inc (NASDAQ:CDNA) released its quarterly earnings results on Thursday, August, 1st. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.07. The company had revenue of $31.45 million for the quarter, compared to analyst estimates of $27.96 million. CareDx had a negative return on equity of 47.53% and a negative net margin of 38.29%. View CareDx's Earnings History.

When is CareDx's next earnings date?

CareDx is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for CareDx.

What guidance has CareDx issued on next quarter's earnings?

CareDx updated its FY 2019 earnings guidance on Thursday, August, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $123-125 million, compared to the consensus revenue estimate of $115.17 million.

What price target have analysts set for CDNA?

5 analysts have issued 1 year target prices for CareDx's shares. Their forecasts range from $35.00 to $63.00. On average, they anticipate CareDx's stock price to reach $47.40 in the next year. This suggests a possible upside of 82.0% from the stock's current price. View Analyst Price Targets for CareDx.

What is the consensus analysts' recommendation for CareDx?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CareDx.

What are Wall Street analysts saying about CareDx stock?

Here are some recent quotes from research analysts about CareDx stock:
  • 1. According to Zacks Investment Research, "CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of transplant surveillance, such as the use of cell-free DNA (cfDNA) as a biomarker for rejection. CareDx, Inc. is based in Brisbane, California. " (10/7/2019)
  • 2. HC Wainwright analysts commented, "Our 12-month price target is based on an estimated market value of the firm at $1.83B, which includes a discounted cash flow analysis based asset value for pre- and post-transplant tests, using a 10% discount rate and 2% terminal growth rate, and assuming 43M shares outstanding at the end of 1Q20. Investment risks include: (1) failure of to achieve commercial success due to market size, penetration rate, and/or competition; and (2) potential dilution risk. CareDx, Inc." (5/9/2019)

Has CareDx been receiving favorable news coverage?

Media coverage about CDNA stock has trended very negative this week, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. CareDx earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for CareDx.

Are investors shorting CareDx?

CareDx saw a increase in short interest in September. As of September 30th, there was short interest totalling 3,140,000 shares, an increase of 49.5% from the August 30th total of 2,100,000 shares. Based on an average daily trading volume, of 982,100 shares, the short-interest ratio is currently 3.2 days. Approximately 8.2% of the shares of the stock are sold short. View CareDx's Current Options Chain.

Who are some of CareDx's key competitors?

What other stocks do shareholders of CareDx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include EXACT Sciences (EXAS), Aduro BioTech (ADRO), Square (SQ), Tandem Diabetes Care (TNDM), Alibaba Group (BABA), Advanced Micro Devices (AMD), Roku (ROKU), NVIDIA (NVDA), Micron Technology (MU) and Sarepta Therapeutics (SRPT).

Who are CareDx's key executives?

CareDx's management team includes the folowing people:
  • Peter K. Maag, Chief Executive Officer & Director
  • Reginald Seeto, President & Chief Business Officer
  • Paul Ciccolella, Senior Vice President-Global Operations
  • Michael Bell, Chief Financial & Principal Accounting Officer
  • James P. Yee, Chief Medical Officer & Executive Vice President

Who are CareDx's major shareholders?

CareDx's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (1.41%) and Juncture Wealth Strategies LLC (0.04%). Company insiders that own CareDx stock include James P Yee, Michael Brian Bell, Michael Goldberg, Mitchell J Nelles, Neil Gagnon, Peter Maag, Sasha King and William A Hagstrom. View Institutional Ownership Trends for CareDx.

Which major investors are buying CareDx stock?

CDNA stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC and Juncture Wealth Strategies LLC. View Insider Buying and Selling for CareDx.

How do I buy shares of CareDx?

Shares of CDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is CareDx's stock price today?

One share of CDNA stock can currently be purchased for approximately $26.04.

How big of a company is CareDx?

CareDx has a market capitalization of $1.10 billion and generates $76.57 million in revenue each year. The company earns $-46,760,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. CareDx employs 227 workers across the globe.View Additional Information About CareDx.

What is CareDx's official website?

The official website for CareDx is http://www.caredxinc.com/.

How can I contact CareDx?

CareDx's mailing address is 3260 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The company can be reached via phone at 415-287-2300 or via email at [email protected]

MarketBeat Community Rating for CareDx (NASDAQ CDNA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  311 (Vote Outperform)
Underperform Votes:  297 (Vote Underperform)
Total Votes:  608
MarketBeat's community ratings are surveys of what our community members think about CareDx and other stocks. Vote "Outperform" if you believe CDNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel